Nevertheless, a recent midterm clinical trial on the second generation anti-CD3 mAb Otelixizumab demonstrated a reduced exogenous insulin request in early diagnosed T1D patient [48]. This evidence concerns the gene INS and type 1 diabetes mellitus.